WALTHAM, MA -- April 18, 2007 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced it has expanded its successful portfolio of high throughput screening (HTS) LANCE® assays with the release of LANCE Ultra. PerkinElmer’s improved LANCE Ultra is a flexible and adaptable homogeneous technology for HTS and uHTS designed specifically for developing and optimizing sensitive assays for a variety of drug discovery targets, with a particular focus on applications for a wide range of kinase targets.

“Protein kinases regulate several important functions within cells, such as growth, proliferation and cell adhesion, making it one of the most important areas of study in today’s pharmaceutical and biotech laboratories,” says Dr. Richard Eglen, vice president and general manager of the Discovery and Research Reagents business of PerkinElmer Life and Analytical Sciences. “The addition of LANCE Ultra to PerkinElmer’s broad offering of TR-FRET assay tools creates one of the industry’s largest portfolios targeting high value functional biochemical and cell based assays.”

LANCE Ultra utilizes ULight™, an innovative, low molecular weight red-shifted fluorescent dye that greatly enhances the performance of Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET) assays by increasing the range of targets that can be identified. Dr. Eglen said, “Dysregulation of kinase activity plays causal roles in many human diseases, making kinases one of today’s most important drug discovery target classes.” LANCE Ultra reagents are specifically engineered for the precise development and optimization of kinase and enzyme assays, as well as for monitoring protein-protein interactions.

Ultra high throughput screening applications such as LANCE Ultra are easily adapted to any TR-FRET capable plate reader such as the PerkinElmer ViewLux™ uHTS imaging system or EnVision™ multimode reader, enabling greatly improved precision and remarkable throughput.

Other LANCE TR-FRET applications from PerkinElmer include LANCE cAMP cell based assay for the analysis and screening of G protein-coupled receptor (GPCR) drug targets and the TruPoint™ assay system, which is ideal for screening for therapeutic modulators of a wide variety of enzyme targets such as proteases and helicases.

In addition to its broad offering of traditional LANCE technologies, PerkinElmer has significantly enhanced its custom reagents service, offering expert labeling of a wide variety of peptides, proteins and antibodies with PerkinElmer’s proprietary europium and lanthanide chelate donor dyes, and ULight or APC acceptor dyes, all developed to the very highest standards.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.